The Novel Immunomodulatory and Anticoagulant Therapies for Recurrent Pregnancy Loss
NCT ID: NCT02990403
Last Updated: 2017-03-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
500 participants
INTERVENTIONAL
2014-10-31
2018-12-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Preconceptional Thromboprophylaxis in Recurrent PREGNANCY LOSSES Caused by Antiphospholipid Syndrome
NCT01661439
Aspirin, Heparin and Miscarriage
NCT01917799
Steroids and Antiphospholipid Syndrome- Related Pregnancy Loss
NCT00180778
The Role of Prothrombin Gene and Methylenetetrahydrofolate Reductase(MTHFR) Gene Polymorphisms as Risk Factors for Recurrent Miscarriage
NCT03209063
Neutrophil Extracellular Traps Mediate Antiphospholipid Antibody-induced Pregnancy Loss
NCT03735108
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
aspirin+LMWH group
aspirin, 75-100mg/day, po,bid + low molecular weight heparin,4100U,hypodermic injection，qd
Aspirin
Heparin
aspirin+LMWH+immunoglobulin group
aspirin, 75-100mg/day, po,bid + low molecular weight heparin,4100IU/day,hypodermic injection,qd + immunoglobulin 300mg/kg（with 100ml normal saline）,intravenous injection,once every two weeks
Aspirin
Heparin
Immunoglobulin
aspirin+LMWH+prednisone group
aspirin, 75-100mg/day, po,bid + low molecular weight heparin,4100IU/day,hypodermic injection,qd + prednisone,5-10mg/day,po,qd
Aspirin
Heparin
Prednisone
aspirin+LMWH+IVIG+prednisone group
aspirin, 75-100mg/day, po,bid + low molecular weight heparin,4100IU/day,hypodermic injection,qd + immunoglobulin 300mg/kg（with 100ml normal saline）,intravenous injection,once every two weeks + prednisone,5-10mg/day,po,qd
Aspirin
Heparin
Prednisone
Immunoglobulin
dydrogesterone group
dydrogesterone 20-30mg/day, po, tid
Dydrogesterone
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Aspirin
Heparin
Prednisone
Immunoglobulin
Dydrogesterone
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
2. with a history of mental illness and/or family history of mental illness limb disabled.
3. taking medicine within one month.
4. suffering major events or having mood swings.
5. having internal and surgical disease(after having variety of physical examination such as electrocardiogram/hepatic and renal function/blood routine and urine routine)
6. chromosome aberrations in anyone of the couple.
7. patients who have drugs contraindications
18 Years
50 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai First Maternity and Infant Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Shihua Bao
Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shanghai first Maternity and Infant health hospital, Tong Ji University
Shanghai, , China
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ShanghaiFMIH-0003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.